Core Viewpoint - Anjess Medical Technology Co., Ltd. reported a revenue of 302 million yuan for the first half of 2025, marking a year-on-year growth of 14.56%, with a net profit of 126 million yuan, reflecting a growth of 1.26% [1] Group 1: Financial Performance - The company achieved a revenue of 302 million yuan, representing a 14.56% increase year-on-year [1] - The net profit attributable to shareholders was 126 million yuan, showing a growth of 1.26% [1] Group 2: R&D Investment - Anjess emphasizes innovation as a key driver for growth, with R&D investment reaching 34.46 million yuan, up 33.29% year-on-year [1] - The company is actively working on 19 design improvement projects for existing products, 40 new product development projects, and 5 preliminary research projects [1] - The subsidiary Hang An Medical Technology (Hangzhou) Co., Ltd. is also advancing R&D with 12 new product development projects and 9 preliminary research projects [1] Group 3: Market Expansion - The domestic market sales revenue was 137 million yuan, an increase of 10.07% year-on-year, while overseas market sales reached 163 million yuan, up 18.29% [2] - Anjess has successfully sold products to over 60 countries across six continents, adding 14 new overseas clients during the reporting period, bringing the total to 130 [2] Group 4: Global Strategy - The company is enhancing its global competitiveness through a globalization strategy, focusing on local operational capabilities [3] - The Dutch subsidiary is operational, improving service capabilities and brand influence in Europe, while the U.S. subsidiary is in preparation to expand into North America [3] - A digital factory is being established in Thailand to integrate automation, smart manufacturing, and green management, aimed at increasing overall capacity and optimizing production layout [3] Group 5: Market Challenges and Opportunities - The company faces challenges in entering the European and American markets due to rising compliance costs and increased concentration of overseas channels, which compresses bargaining power [3] - The micro-invasive technology market in China is expected to grow, providing opportunities for Anjess to focus on smaller endoscope platforms and accelerate product registration [3]
安杰思上半年营收突破3亿元 持续加码研发与全球布局